Omalizumab to Accelerate a Symptom-driven Multi-food OIT

Clinical trial NCT04045301 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04045301
Sponsor: Philippe Bégin
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Food IgE-mediated Allergy Immunotherapy Omalizumab Physiological Effects of Drugs

Start date: 2019-11-11
Primary completion: 2025-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.